CASI Pharmeceuticals

Analyst Coverage

CASI Pharmaceuticals, Inc. is followed by the analyst(s) listed below. This list is provided for information purposes only. Please note that any opinions, estimates or forecasts regarding CASI Pharmaceutical’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of CASI Pharmaceuticals or its management. Analysts may be contacted directly for copies of their reports.

HC Wainwright & Co. Swayampakula Ramakanth (RK), Ph.D.
Zacks Small Cap Research Grant Zeng, CFA

About Us

A leading US-headquartered, NASDAQ-listed, biopharmaceutical company targeting the global market, with a focus on China.

Learn More

In the News

CASI's turnaround turns eastward; firm seeks to be Celgene of China

Read Article →


Kinase Inhibitor Demonstrates Efficacy in a Patient-Derived Xenograft Model of Fibrolamellar Hepatocellular Carcinoma featuring DNAJB1-PRKACA Fusion

Download →


Evaluation Of ENMD-2076 In Combination With Anti-PD1 In Syngeneic Cancer Models

Download →